Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

AstraZeneca trumpets the good data they found for Tagrisso in an adjuvant setting for NSCLC — but many of the experts aren’t cheering along

16 hours ago

Ironwood, AbbVie kick delayed-release Linzess formulation to the curb after trial failure

2 hours ago

Capitalizing Pablo: The world’s biggest drug royalty buyer is going public. And the low-key CEO divulges a few ...

23 hours ago

Kura flashes positive HRAS data on once-failed J&J drug

14 minutes ago

Latest

Most read

Sanofi CEO Paul Hudson has $23B burning a hole in his pocket. And here are some hints on how he plans to spend that

2 days ago

After starring at ASH last fall, Gilead’s new Forty Seven crew colors in more promising data for magrolimab at ASCO

25 minutes ago

Headed to PhII: Allogene CEO David Chang completes a positive early snapshot of their off-the-shelf CAR-T pioneer

1 hour ago

Pfizer, Merck KGaA cement Bavencio bladder cancer win with OS data — while carving another niche in rare cancer

1 hour ago

Sanofi brings in 4 new executives in continued shake-up, as vaccines and consumer health chief head out the door

1 hour ago

Looking to move past an R&D fiasco, Ipsen poaches their new CEO from Sanofi

2 hours ago

see latest stream

People

Drug developer, Big Pharma commercial exec, now an upstart biotech chief — Fabrice Chouraqui is ready to try ...

Yesterday

Stymied by the pandemic, Immunomedics' new CEO bows out, taking a million bucks plus perks as he heads out the ...

Yesterday

Ex-biotech chief pleads guilty in college admissions scandal, faces a 10-month prison stretch in plea deal

2 days ago

Startups

For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen complement play

2 days ago

Daphne Koller’s AI startup gets $143M in new cash from a16z, others

2 days ago

Bezos, Paul Allen funds, a16z put up $100M to build an Illumina of human proteins

Last week

Deals

UPDATED: Gilead leases partner rights to TIGIT, PD-1 in a $2B deal with Arcus. Now comes the hard part

2 days ago

In latest cancer deal, Bristol Myers Squibb's new BD chief bets $65M in search for more targets like PARP

2 days ago

PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in ...

2 days ago

IPOs

As biotech IPOs sizzle on virtual Wall Street, 3 new players roll the dice on megamoney gambles topping $325M

2 days ago

A little-known biotech running low on cash looks to get its own $100M IPO from pandemic market

Last week

Two years in, Hong Kong’s biotech experiment has been validated

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

MacroGenics CEO Scott Koenig gets the pre-ASCO party started with some encouraging pipeline tidbits — leaving lots ...

3 weeks ago

Dealmaking spiked to record levels in April as Covid-19 triggered a fever of partnering. But what happens to ...

4 weeks ago

Full steam ahead, Pfizer goes bargain hunting in an age of coronavirus — with a special focus on cancer and rare ...

5 weeks ago

A slice of half-baked remdesivir data takes a dark turn — but we're still waiting for a definitive study

Last month

Don't missSee all

Novartis jumps into Covid-19 vaccine hunt, as Big Pharma and big biotech commit to billions of doses

22 hours ago

Covid-19 roundup: FDA's Stephen Hahn personally helped a doctor set up hydroxychloroquine trial — report

Yesterday

Covid-19 roundup: Buoyed by soaring shares, Novavax inks a $167M deal to buy Covid-19 vaccine-making facility; France ...

2 days ago

Bristol Myers Squibb finally gets in the frontline NSCLC game dominated by Merck, adding a second Opdivo/Yervoy-based ...

2 days ago

Endpoints Standouts

The 20 under 40: Inside the next generation of biopharma leaders

Last month

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

4 months ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

6 months ago

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

7 months ago

Peer review See all

May

22

The man who led Gilead’s autoimmune pivot heads to Boston; Novartis gets a new chief for its AI Innovation Center

May

15

Cherry Thomas joins Caribou as SVP of clinical development; Artax locks in Joseph Lobacki as CEO

May

8

Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO

May

1

High-profile R&D specialist David Lebwohl jumps to new job as CMO of a pioneering CRISPR player; Troubled AMAG ...

Apr

24

Laura Shawver on why she came back after an $88M windfall; MorphoSys taps Amgen vet as CCO

R&D channel feed

3 days ago

UPDATED: Backed by BARDA, Merck jumps into Covid-19: buying out a vaccine, partnering on another and adding antiviral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move. Tuesday morning the pharma ...

READ MORE

Venrock survey shows growing recognition of coronavirus toll, waning confidence in arrival of vaccines and treatments

Yesterday

Alnylam nabs speedy review, setting up 3rd possible approval in 3 years

2 days ago

latest in R&D

In for the long vaccine game, Merck buys into patch delivery tech with pandemic potential

22 hours ago

Denali unveils new way of crossing blood brain barrier as the big neuroscience bet enters its clinical years

Yesterday

UPDATED: GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight

Yesterday

UPDATED: Dupixent clears PhIII trial in new disease as blockbuster looks to expand past Regeneron-Sanofi split

2 days ago

Beyond cold storage: Technology designed to keep organs warm, helps liver transplant patients in key study

2 days ago

see latest stories

Pharma channel feed

6 days ago

German Merck bests US Merck in UK copyright tussle of Merck v. Merck

Before Merck and Merck, there was only Merck. A single company was founded as a drugmaker in the pre-Bismarckian days of an industrializing Germany that, in 1891, decided to launch an ...

READ MORE

FDA approves the first generic for Amarin's Vascepa — but is a fish oil price war imminent?

6 days ago

Parkinson's patients no longer need to rely on a needle for apomorphine antidote for 'off' episodes after new FDA ...

Last week

latest in Pharma

Once valued at $4B, an embattled Akorn — nursing a market cap of roughly $37M — files for bankruptcy

Last week

AstraZeneca, Merck push blockbuster franchise to another key FDA approval, relegating a rival to second-fiddle status

Last week

Bristol Myers Squibb spells out OS benefit of Opdivo/Yervoy combo plus 'limited' chemotherapy — is it enough to change practice?

3 weeks ago

AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval

3 weeks ago

Novartis lands capmatinib approval, giving them a second potential blockbuster from Incyte

4 weeks ago

see latest stories

Coronavirus channel feed

2 days ago

Biotech Voices: Coronavirus will change biotech research with remote collaborations

When a field that depends on scientific benchwork suddenly moves online, what happens to collaborations and the innovation supply chain? We are seeing the answer to this question play ...

READ MORE

Covid-19 roundup: Junshi, Eli Lilly ready to launch Covid-19 antibody trial; Janet Woodcock steps aside — for now ...

3 days ago

FDA explains impact of Covid-19 on applications, formal meetings

Yesterday

latest in Coronavirus

Researchers define exactly what they saw in the first positive remdesivir study for Covid-19. But what's that worth to Gilead?

5 days ago

Covid-19 roundup: CanSino beats Moderna to publication of first-in-human data for a coronavirus vaccine

Last week

EMA extends virtual-only meeting policy through August

Last week

Covid-19 roundup: BARDA hands AstraZeneca $1B-plus to race through PhIII and ramp up fall deliveries of Oxford’s pandemic vaccine

Last week

Mammoth Biosciences teams with GSK to put Covid-19 CRISPR tests at home, airports, borders

Last week

see latest stories